Jacobson, Caron A.
Harvard University · Dana-Farber Cancer Institute
13 papers on CoChatORCID 0000-0002-0180-0654
Most cited papers
- Verified
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 6,030
- Verified
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 2,286
- Verified
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 1,862
- Verified
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 1,607
- Verified
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., et al. (2020) · Blood Advances
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 489
- Verified
Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity
Jacobson, C. A., Hunter, B. D., Redd, R., Rodig, S. J., Chen, P.-H., Wright, K., Lipschitz, M., Ritz, J., Kamihara, Y., Armand, P., et al. (2020) · Journal of Clinical Oncology
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 352
- Verified
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell
Acute Lymphoblastic Leukemia researchAcute Myeloid Leukemia Research
Cited by 295
- Verified
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
Plaks, V., Rossi, J. M., Chou, J., Wang, L., Poddar, S., Han, G., Wang, Z., Kuang, S.-Q., Chu, F., Davis, R. E., et al. (2021) · Blood
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 199
- Verified
The public repository of xenografts enables discovery and randomized phase II-like trials in mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell
Acute Lymphoblastic Leukemia researchAcute Myeloid Leukemia Research
Cited by 80
- Verified
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Jacobson, C., Kopp, N., Layer, J. V., Redd, R. A., Tschuri, S., Haebe, S., van Bodegom, D., Bird, L., Christie, A. L., Christodoulou, A., et al. (2016) · Blood
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 45
- Verified
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis
Kelkar, A. H., Cliff, E. R. S., Jacobson, C. A., Abel, G. A., Dijk, S. W., Krijkamp, E. M., Redd, R., Zurko, J. C., Hamadani, M., Hunink, M. G. M., et al. (2023) · Annals of Internal Medicine
CAR-T cell therapy researchHealth Systems, Economic Evaluations, Quality of Life
Cited by 31
- Verified
A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Siddiqi, T., Jacobson, C. A., Westin, J. R., Chavez, J. C., Ghobadi, A., Herrera, A. F., LaCasce, A. S., et al. (2016) · Blood
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 27
- Verified
Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence
Chen, P.-H., Lipschitz, M., Wright, K., Armand, P., Jacobson, C. A., Roberts, Z. J., Rossi, J. M., Bot, A., Go, W. Y., & Rodig, S. J. (2018) · Blood
CAR-T cell therapy researchCancer Immunotherapy and Biomarkers
Cited by 6
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free